Cover Image
市場調查報告書

全球便秘市場

Global Constipation Market Report: 2016 Edition

出版商 Koncept Analytics 商品編碼 355970
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
全球便秘市場 Global Constipation Market Report: 2016 Edition
出版日期: 2016年04月11日 內容資訊: 英文 52 Pages
簡介

便秘,主要分為慢性特發性便秘 (CIC) 、大腸躁鬱症 (IBS) 、類鴉片物質誘發性便秘 (OIC) 3種。

本報告提供全球便秘市場相關調查分析,尤其是以美國、日本、中國、歐洲為焦點,提供主要趨勢,成長推動因素,課題,主要企業簡介等系統性資訊。

第1章 市場概要

  • 簡介
  • 種類
  • 病因/原因
  • 治療選項

第2章 便秘市場分析

  • 美國
  • 日本
  • 中國

第3章 慢性便秘市場分析

  • 美國
  • 歐洲

第4章 大腸躁鬱症 (IBS) 市場分析

  • 美國
  • 歐洲

第5章 類鴉片物質誘發性便秘 (OIC) 市場分析

  • 美國
  • 歐洲

第6章 市場動態

  • 成長推動因素
  • 主要趨勢
  • 課題

第7章 競爭情形

第8章 企業簡介

  • Sucampo Pharmaceuticals, Inc.
  • Synergy Pharmaceuticals, Inc.
  • AstraZeneca
  • Ironwood Pharmaceuticals

圖表

目錄

Constipation is a common medical condition common among elderly and women, and is interpreted differently by patients and physicians. Constipation can be chronic, sometimes severe, and has a significant, even deliberating effect on the quality of life of a patient. Various treatment options are available for the treatment of constipation and patients often adopt different over-the-counter remedies for the same. There exist three main types of constipation including Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome (IBS-C) and Opioid Induced Constipation (OIC).

There exist vast opportunities for prescription drugs in the constipation market. However, OTC drugs and laxatives are generally used for treating constipation, patients and physicians have started recognizing the importance of branded drugs. Future growth of the constipation market is based on continued growth of prescription therapies to treat constipation, increased research and development of novel drugs by biopharmaceutical companies, increasing patient and physician awareness of effective prescription alternatives to Over-the-Counter medications.

Growth of the constipation market is driven by several factors including rising prescription opioid consumption, growing ageing population, vast opportunity for drugs with significant potential in the U.S., rising spending on medicines, growing female population and rising healthcare expenditure. However, the growth of the market can be hindered by certain challenges including rising tide of OTC drugs for constipation and lower awareness of prescription medication for OIC.

The report, “Global Constipation Market” analyzes the currently prevailing condition of the market along with its future scope of development. The specific markets of the U.S. Japan China and Europe are being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.

Table of Contents

1. Market Overview

  • 1.1. Introduction
  • 1.2. Types
    • 1.2.1. Chronic Idiopathic Constipation (CIC)
    • 1.2.2. Irritable Bowel Syndrome with Constipation (IBS-C)
    • 1.2.3. Opioid-Induced Constipation (OIC)
  • 1.3. Etiology/ Causes
    • 1.3.1. Extrinsic Causes
    • 1.3.2. Intrinsic Causes
  • 1.4. Treatment Options
    • 1.4.1. Pharmacological Treatment
    • 1.4.2. Non Pharmacological Treatments

2. Constipation Market Analysis

  • 2.1. The U.S.
    • 2.1.1. The U.S. Constipation Market by Value
    • 2.1.2. The U.S. Constipation Market Value by Type
    • 2.1.3. The U.S. Constipation Market by Volume
    • 2.1.4. The U.S. Constipation Market Volume by Type
    • 2.1.5. The U.S. Constipation Market by Drug Type
    • 2.1.6. The U.S. Constipation Market by Drug
  • 2.2. Japan
    • 2.2.1. Japan's Constipation Market by Volume
    • 2.2.2. Japan's Constipation Drug Market
  • 2.3. China

3. Chronic Constipation Market Analysis

  • 3.1. The U.S. Chronic Constipation Market by Volume
  • 3.2. European Chronic Constipation Market by Volume

4. Irritable Bowel Syndrome Market Analysis

  • 4.1. The U.S. IBS-C Market by Volume
  • 4.2. European IBS-C Market by Volume

5. Opioid Induced Constipation Market Analysis

  • 5.1. The U.S. Opioid Induced Constipation Market by Volume
    • 5.1.1. The U.S. Opioid Induced Constipation Drugs Market
  • 5.2. European Opioid Induced Constipation Market by Volume
    • 5.2.1. European Opioid Induced Constipation Drug Market

6. Market Dynamics

  • 6.1. Growth Drivers
    • 6.1.1. Rising Consumption of Prescription Opioid Drugs in the U.S.
    • 6.1.2. Growing Ageing Population
    • 6.1.3. Vast Opportunity with Significant Potential in the U.S.
    • 6.1.4. Global Spending on Medicines
    • 6.1.5. Growing Female Population
    • 6.1.6. Rising Healthcare Expenditure
  • 6.2. Key Trends
    • 6.2.1. Drugs under Development for Constipation
    • 6.2.2. Market Opportunity for Pediatric Constipation
  • 6.3. Challenges
    • 6.3.1. Rising Tide of Over-The-Counter Drugs for Constipation
    • 6.3.2. Low Awareness of Prescription Medications for OIC

7. Competitive Landscape

8. Company Profiles

  • 8.1. Sucampo Pharmaceuticals, Inc.
    • 8.1.1. Business Overview
    • 8.1.2. Financial Overview
    • 8.1.3. Business Strategies
  • 8.2. Synergy Pharmaceuticals, Inc.
    • 8.2.1. Business Overview
    • 8.2.2. Financial Overview
    • 8.2.3. Business Strategies
  • 8.3. AstraZeneca
    • 8.3.1. Business Overview
    • 8.3.2. Financial Overview
    • 8.3.3. Business Strategies
  • 8.4. Ironwood Pharmaceuticals
    • 8.4.1. Business Overview
    • 8.4.2. Financial Overview
    • 8.4.3. Business Overview

List of Charts

  • The U.S. Constipation Market by Value (2011-2014)
  • The U.S. Constipation Market Value by Type (2011-2014)
  • The U.S. Constipation Market by Volume (2012-2014)
  • The U.S. Constipation Market Volume by Type (2012-2014)
  • The U.S. Constipation Prescription Market by Drug Type (2015E)
  • The U.S. Amitiza Drug Market by Value (2015E-2020E)
  • The U.S. Plecanatide Drug Market by Value (2017E-2025E)
  • The U.S. Plecanatide Penetration Rate by Type (2017E-2025E)
  • Japan's Constipation Market by Volume (2015E-2025E)
  • Japan's Amitiza Drug Market Revenue and Penetration (2015E-2021E)
  • China's Constipation Market by Volume (2015E-2025E)
  • The U.S. Chronic Constipation Market by Volume (2014-2025E)
  • European Chronic Constipation Market by Volume (2014-2025E)
  • The U.S. IBS-C Market by Volume (2014-2025E)
  • European IBS-C Market by Volume (2014-2025E)
  • The U.S. Opioid Induced Constipation Market by Volume (2015-2025E)
  • The U.S. Dolcanatide Market by Value (2019E-2025E)
  • European Opioid Induced Constipation Market by Volume (2015-2025E)
  • European Dolcanatide Market by Value (2020E-2027E)
  • Growing Prescription Opioid Drugs in the U.S. (2000-2014E)
  • Global Ageing Population Over 65 (2009-2014)
  • The U.S. Constipation Market by Branded/Non-Branded Therapy (2014)
  • The U.S. Constipation Market by Therapy (2015E-2020E)
  • Global Spending on Medicines (2010-2020E)
  • Global Female Population (2010-2014)
  • Global Healthcare Expenditure Per Capita (2009-2014E)
  • Global OTC Market CAGR Growth Rate (2011-2016)
  • Awareness of OIC Prescription Medications among Patients (2015)
  • Sucampo Revenue by Geographical Segments (2013/2014)
  • Sucampo Revenue and Net Income (2010-2014)
  • Synergy Pharmaceuticals Revenue and Net Income (2014-2018E)
  • Synergy's Research and Development Expenditure (2011-2015)
  • AstraZeneca Revenue by Therapeutic Segment (2015)
  • AstraZeneca Revenue by Regions (2015)
  • AstraZeneca Revenue and Net profit (2010-2015)
  • Ironwood Pharmaceutical's GI and Vascular/Fibrotic Platforms
  • Ironwood's Revenue* and Net Loss (2011-2015)

List of Tables

  • Current Treatment Options for Constipation
  • Pipeline Drugs under Development for Constipation
  • Opportunity in Pediatric & Elderly Constipation
  • Global Constipation Competitors Comparison
  • Near-Term Clinical Pipelines of Sucampo
  • Synergy Pharmaceuticals Clinical-Stage Pipelines
Back to Top